title: Effect of iron as a new type of phosphate binder in hemodialysis patients.
abstract: Hyperphosphatemia is one of the major problems requiring management in the majority of hemodialysis patients and they require phosphate-binding agents to control the hyperphosphatemia. Aluminum hydroxide and calcium compounds are used currently as phosphate-binding agents to treat hyperphosphatemia, but these compounds can cause undesirable side effects. Therefore, the development of new phosphate-binding agents is imperative. It is well known that oral and intravenous administration of iron causes hypophosphatemia. We hypothesized that this side effect of iron may be beneficial for the treatment of hyperphosphatemia in hemodialysis patients. Consequently, we conducted a fundamental and clinical investigation of the effects of iron administration. Membrane permeability of phosphorus in a mixture of sodium ferrous citrate and dessicated aluminium hydroxide in the presence of hydrogenated lecithin as a phosporic compound was examined. Fifteen patients undergoing hemodialysis were treated with 150 mg of sodium ferrous citrate given orally for eight weeks. The permeability of the filtering membrane to phosphorus decreased in accordance with the dosage of sodium ferrous citrate and dessicated aluminum hydroxide. The degree of phosphate-binding effect of sodium ferrous citrate was larger than that of dessicated aluminum hydroxide. Serum phosphorus decreased significantly during the experiment. These results suggest that the oral administration of sodium ferrous citrate as a new phosphate binder is a useful therapeutic method for hemodialysis in patients with hyperphosphatemia.
authors.affiliation: Department of Clinical Research, National Okura Hospital, Tokyo, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Kuroda
authors.forename: M
authors.initials: M
authors.lastname: Komori
authors.forename: K
authors.initials: K
authors.lastname: Nagamatsu
authors.forename: R
authors.initials: R
authors.lastname: Ninomiya
authors.forename: K
authors.initials: K
authors.lastname: Maejima
authors.forename: K
authors.initials: K
authors.lastname: Hasegawa
authors.forename: M
authors.initials: M
authors.lastname: Samejima
authors.forename: M
authors.initials: M
authors.lastname: Kuroda
authors.forename: H
authors.initials: H
authors.lastname: Fujimori
authors.forename: M
authors.initials: M
authors.lastname: Kasai
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D019343:Citric Acid; D005260:Female; D005293:Ferritins / Q000097:blood; D005296:Ferrous Compounds / Q000008:administration & dosage; D006801:Humans; D007501:Iron / Q000008:administration & dosage* / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000378:metabolism*; D006435:Renal Dialysis
chemical_list: D005296:Ferrous Compounds; D010710:Phosphates; D019343:Citric Acid; C016600:ferrous citrate; D005293:Ferritins; D007501:Iron